PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

32

description

BMJ 2002;324:698 ( 23 March ) News extra Psychologists allowed to prescribe drugs for mental illness Deborah Josefson Nebraska New Mexico has become the first US state to allow psychologists to prescribe drugs. The American Psychological Association has been lobbying since 1984 to gain legislative support for bills that authorize psychologists to prescribe psychiatric drugs. The association argues that it is more cost effective for patients to receive their psychotherapy and drug treatment from one practitioner. Before New Mexico’s act, only the US territory of Guam allowed psychologists to prescribe drugs. Guam lumped psychologists with physician assistants as allied healthcare specialists with prescribing privileges in 1998, but to date no psychologists there have taken advantage of the law.

Transcript of PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

Page 1: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.
Page 2: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.
Page 3: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

BMJ 2002;324:698 ( 23 March )News extraPsychologists allowed to prescribe drugs for mental illnessDeborah Josefson Nebraska New Mexico has become the first US state to allow psychologists to prescribe drugs.

The American Psychological Association has been lobbying since 1984 to gain legislative support for bills that authorize psychologists to prescribe psychiatric drugs. The association argues that it is more cost effective for patients to receive their psychotherapy and drug treatment from one practitioner.

Before New Mexico’s act, only the US territory of Guam allowed psychologists to prescribe drugs. Guam lumped psychologists with physician assistants as allied healthcare specialists with prescribing privileges in 1998, but to date no psychologists there have taken advantage of the law.

Page 4: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

Louisiana also allows psychologists (2004)

Page 5: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.
Page 6: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.
Page 7: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.
Page 8: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

Some general points to begin…… A bit of history

Page 9: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

1. The focus of this course is pharmacotherapy

2. The practice of pharmacotherapy cannot be oversimplified (ie one illness - one type of pill)

3. Many variables impinge on adherence/ compliance and prescriptions can have tremendous variation for individuals

Page 10: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.
Page 11: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

4. Ways to characterize drugsa. chemical structure

b. chemical name -

N-(-4-hydroxyphenyl) acetamide

Page 12: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

c. generic name or nonproprietary name

acetaminophen

- can be useful sometimes because they give clue to the nature of the drug

ex. bz, local anesthetics

** textbooks, scientific discussions of drug use generic name

Page 13: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

d. Trade name-

ex. Luvox fluvoxaminePaxil paroxetineNamenda memantineAricept donepazilLunesta eszopiclone

What is the trade name for acetaminophen?

Page 14: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.
Page 15: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

active ingredients - same in trade vs generic◦ inactive ingredients may be different

Page 16: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

e. New novel compounds -

Clinicaltrials.gov

Page 17: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.
Page 18: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

CP 101,606 - traxoprodil

◦ stroke, ◦ dyskinesias◦ Parkinson’s Disorder◦ Postoperative disorder◦ Alcohol-induced neurotoxicity

Page 19: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

Typical cost for a drug to reach market

Screening tests using animal models

Page 20: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

ensures that drugs are safe and effective.

Page 21: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.
Page 22: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

http://www.fda.gov/cder/index.html

Page 23: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

Screening tests using animal models Phase 1 - assessment of safety and

toxicity small n, small dose

Phase 2 - tested in limited n of patients individuals with condition ~ few hundred patients

Phase 3 - Expanded clinical trials usually administered to thousands

Page 24: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

3 phases (or 4) Phase 1 – early 1800’s –

◦ isolation of morphine from opium in 1805

Page 25: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

early 1800’s –◦ isolation of morphine from opium in 1805

1855 – invention of hypodermic needle used in agitation, aggression in psychiatric hospitals

Page 26: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

2nd phase early 1900’s

◦ first barbiturate synthesized in 1903◦ phenobarbital in 1912

by 1950’s – 2500 preps and 50 used clinically as anticonvulsant, sedative-hypnotic,

Page 27: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

insulin-◦ introduced to psychiatry in 1920’s to stimulate

appetite and produce ◦ 1930’s – alleviating morphine withdrawal and

treating schizophrenia

Page 28: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

development of barbiturates (first 1/2 of 20th century)

Lithium’s usefulness in treating bipolar (1949).

Page 29: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

1950’s to current◦ introduction of more current psychotropics

Page 30: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.
Page 31: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.

introduction of new drug discovery methods◦ ability to recreate and determine genetic

components of various neurotransmitter receptor subtypes

Page 32: PSY 565 – Topics in Behavioral Neuroscience Clinical Psychopharmacology.